CLINICAL_TRIALS
trial_result
· 2024-03-29
Clinical Trial Update: Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients [Phase 2]
Summary
Phase 2 trial update on safety of Ruconest in children aged 2-13 with hereditary angioedema has been completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pharming Technologies B.V. | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED | Results posted: 2024-03-29